The US Food and Drug Administration (FDA) announced today, Thursday, that it has approved FluMist, the nasal influenza vaccine, for the treatment of healthy young children between 2 and 5 years old. This increases the range of patients in the US that can now be treated with the vaccine, which previously was limited to healthy children over 5 and adults up to the age of 49.
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment